Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) Gross Profit (2016 - 2025)

OptimizeRx's Gross Profit history spans 13 years, with the latest figure at $17.5 million for Q3 2025.

  • For Q3 2025, Gross Profit rose 30.26% year-over-year to $17.5 million; the TTM value through Sep 2025 reached $71.5 million, up 29.57%, while the annual FY2024 figure was $59.4 million, 38.41% up from the prior year.
  • Gross Profit for Q3 2025 was $17.5 million at OptimizeRx, down from $18.6 million in the prior quarter.
  • Across five years, Gross Profit topped out at $22.0 million in Q4 2024 and bottomed at $6.1 million in Q1 2021.
  • The 5-year median for Gross Profit is $11.7 million (2024), against an average of $11.9 million.
  • The largest annual shift saw Gross Profit fell 12.96% in 2023 before it skyrocketed 64.19% in 2024.
  • A 5-year view of Gross Profit shows it stood at $12.4 million in 2021, then rose by 0.51% to $12.5 million in 2022, then soared by 43.25% to $17.8 million in 2023, then grew by 23.44% to $22.0 million in 2024, then fell by 20.46% to $17.5 million in 2025.
  • Per Business Quant, the three most recent readings for OPRX's Gross Profit are $17.5 million (Q3 2025), $18.6 million (Q2 2025), and $13.3 million (Q1 2025).